Nt Minerals Limited

NTM

NT Minerals Ltd. engages in the exploration and mining for copper. The firm's projects include the Redbank Project and the Millers Creek Project. The Redbank Project is located in the east McArthur Basin and spans an area from the Northern Territory/Queensland border west towards Glencore’s McArthur Mine. The Millers Creek Project is located approximately 700 kilometers (km) northwest of Adelaide and consists of real estate situated between mining companies OZ Minerals to the north and FMG to the east. The Millers Creek Project comprises two exploration licenses over 1,110 square kilometers (km2) of tenure in the Gawler Craton in South Australia. The tenements, EL6247 (Millers Creek) and EL6321 (Kingoonya) are in the iron-oxide copper gold or IOCG Belt, hosting IOCG deposits including Olympic Dam and Prominent Hill.

Northern Minerals Limited

NTU

Northern Minerals Ltd. engages in the exploration, evaluation, and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-11-15. The company owns 100% of the Browns Range Project (Project) in northern Western Australia, tenements rich in the heavy rare earth elements dysprosium (Dy) and terbium (Tb). The Browns Range Project is located approximately 160 kilometers south-east of Halls Creek on the northern edge of the Tanami Desert in Western Australia. Its other projects include John Galt and Boulder Ridge. The John Galt Project comprises four 100% owned tenements which cover a combined area of 78 square kilometers. The project area is situated in the East Kimberley region of Western Australia, approximately 200 kilometers (km) south of Kununurra and 35 km from the Great Northern Highway. The Company’s Boulder Ridge Project is part of a tenement package covering the NT portion of the Browns Range Dome and extends southward toward the Tanami Gold mine. The John Galt Project comprises granted tenements, such as E80/4298, E80/4967, E80/5070, and E80/5230.

Neurotech International Limited

NTI

Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. The company has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.